Skip to main content
U.S. flag

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock (  ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Find more clinical trials

Brain Stimulation Using Light and Music for Early-Stage Alzheimer's Disease

Start: July 1, 2022
End: June 2027
Enrollment: 60

What Is This Study About?

This study will examine the effects of a noninvasive brain stimulation treatment that combines gamma light therapy and music to improve cognition in people with early-stage Alzheimer's disease. For two months, all participants will use a brain stimulation device. The participants will be randomly assigned to use either a device emitting light that stimulates gamma waves in the brain or a different light, for comparison. At the start and end of the two-month study, participants will complete cognitive and electroencephalogram tests. Researchers will measure changes in cognition and brain activity.

Do I Qualify To Participate in This Study?

Minimum Age: 50 Years

Maximum Age: 95 Years

Must have:

  • Early-stage Alzheimer's, based on testing at study screening, including:
    • Reported memory loss
    • Clinical Dementia Rating global score of 0.5 (with a memory box score of 0.5 or 1.0)
    • Mini-Mental State Examination score of 20-24
    • Positive amyloid blood test
  • Availability of a study partner who can answer questions about behavior

Must NOT have:

  • Any unstable medical condition
  • History of stroke, with a Modified Hachinski Ischemic score < 4
  • Serious psychiatric disorders, including:
    • Depression, with a Geriatric Depression Scale score < 10
    • History of substance or alcohol abuse
  • If taking any medications with psychotropic effects (including cholinesterase inhibitors, memantine, and antidepressants), dosage must be stable for at least three months before study
  • Any conditions that may make having an MRI brain scan unsafe (e.g., metal shrapnel, heart pacemaker, severe claustrophobia, epilepsy) 
  • Moderate or severe hearing loss (> 40dB), based on hearing test

If I Qualify, Who Do I Contact?

Contact study personnel listed either under the general study contact or the location nearest you.

 

Need Help?

Contact NIA’s Alzheimer’s and related Dementias Education and Referral (ADEAR) Center at 800-438-4380 or email ADEAR.

Where Is This Study Located?

Massachusetts
Northeastern University
Boston, MA 02115
Recruiting
Eva Wu

Who Sponsors This Study?

Lead: Northeastern University

Source: ClinicalTrials.gov ID: NCT05984524

 

alzheimers.gov

An official website of the U.S. government, managed by the National Institute on Aging at the National Institutes of Health